<Record>
<Term>Anti-Obesity Agents</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<ParentTerm>Central Nervous System Agents</ParentTerm>
<ClassificationPath>Chemical Actions and Uses/Pharmacologic Actions/Therapeutic Uses/Central Nervous System Agents/Anti-Obesity Agents</ClassificationPath>
<BroaderTerm>Therapeutic Uses</BroaderTerm>
<BroaderTerm>Pharmacologic Actions</BroaderTerm>
<BroaderTerm>Anti-Obesity Agents</BroaderTerm>
<BroaderTerm>Chemical Actions and Uses</BroaderTerm>
<BroaderTerm>Central Nervous System Agents</BroaderTerm>
<ChildTerm>Appetite Depressants</ChildTerm>
<Synonym>Anti-Obesity Agents</Synonym>
<Synonym>Anti Obesity Agents</Synonym>
<Synonym>Anti-Obesity Drugs</Synonym>
<Synonym>Anti Obesity Drugs</Synonym>
<Synonym>Antiobesity Drugs</Synonym>
<Synonym>Antiobesity Agents</Synonym>
<Synonym>Weight-Loss Agents</Synonym>
<Synonym>Weight Loss Agents</Synonym>
<Synonym>Weight-Loss Drugs</Synonym>
<Synonym>Weight Loss Drugs</Synonym>
<Description>Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.</Description>
<Source>MeSH</Source>
</Record>
